Clinical trials of olmesartan

TrialResults-center www.trialresultscenter.org

1 hypertension

<table>
<thead>
<tr>
<th>Trial Treatments</th>
<th>Patients</th>
<th>Trials design and methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>olmesartan 40 mg vs olmesartan 20 mg plus a calcium-channel blocker</td>
<td>high-dose olmesartan 40 mg per day versus 20-mg/day olmesartan combined with standard dose of amlodipine or azelnidipine</td>
<td>high-risk elderly Japanese hypertension patients</td>
</tr>
</tbody>
</table>

OSCAR, 2011:

More details and results:
- anti hypertensive agents for hypertension in all type of patient at http://www.trialresultscenter.org/go-Q13
- angiotensin-receptor blockers for hypertension in all diseases requiring ACEi (HF, CHD, IIT,...) at http://www.trialresultscenter.org/go-Q125

References

OSCAR, 2011:


2 miscellaneous

<table>
<thead>
<tr>
<th>Trial Treatments</th>
<th>Patients</th>
<th>Trials design and methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>olmesartan vs placebo</td>
<td>continued...</td>
<td>continues...</td>
</tr>
<tr>
<td>Trial</td>
<td>Treatments</td>
<td>Patients</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ROADMAP, 2010</td>
<td>olmesartan at 40 mg/day versus placebo</td>
<td>patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction</td>
</tr>
<tr>
<td>[NCT00185159]</td>
<td>n=2232/2215 follow-up: 3.2 y</td>
<td></td>
</tr>
<tr>
<td>ORIENT</td>
<td>olmesartan versus placebo</td>
<td>patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus</td>
</tr>
<tr>
<td>[NCT00141453]</td>
<td>n=282/284 follow-up:</td>
<td></td>
</tr>
<tr>
<td>OSRAR, 2011</td>
<td>high-dose olmesartan 40 mg per day versus</td>
<td>high-risk elderly Japanese hypertension patients</td>
</tr>
<tr>
<td>[NCT00134160]</td>
<td>20-mg/day olmesartan combined with standard dose of amlodipine or azelnidipine</td>
<td></td>
</tr>
<tr>
<td>n=578/586</td>
<td>follow-up:</td>
<td></td>
</tr>
</tbody>
</table>

More details and results:

- angiotensin-receptor blockers for miscellaneous in all type of patients at [http://www.trialresultscenter.org/go-Q425](http://www.trialresultscenter.org/go-Q425)

References

ROADMAP, 2010:


ORIENT, 2011:


3 atrial fibrillation
Trial Treatments Patients Trials design and methods

| **Olmesartan vs placebo** | **Olmesartan 40mg daily** versus placebo | Patients with paroxysmal atrial fibrillation | Parallel groups double blind

**ANTIPAF ongoing** [NCT00098137] n=214/211 Follow-up: 12 months

More details and results:

- Prevention for atrial fibrillation in patients with history of atrial fibrillation at http://www.trialresultscenter.org/go-Q328

**References**

**ANTIPAF**:
ongoing trial NCT00098137

## 4 diabetes type 2

<table>
<thead>
<tr>
<th><strong>Trial</strong></th>
<th><strong>Treatments</strong></th>
<th><strong>Patients</strong></th>
<th><strong>Trials design and methods</strong></th>
</tr>
</thead>
</table>

| **Olmesartan vs placebo** | Olmesartan at 40 mg/day versus placebo | Patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | Parallel groups double-blind Europe (19 countries) |

**ROADMAP**, 2010 [NCT00185159] n=2232/2215 Follow-up: 3.2 y

- Anti hypertensive agents for diabetes type 2 in patients with or without hypertension at http://www.trialresultscenter.org/go-Q414
- Angiotensin-receptor blockers for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q427
- Angiotensin renin system blockade for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q438

**ORIENT** [NCT00141453] n=282/284 Follow-up:

- Patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes

More details and results:

- Prevention for atrial fibrillation in patients with history of atrial fibrillation at http://www.trialresultscenter.org/go-Q328

**References**

**ANTIPAF**:
ongoing trial NCT00098137

## 4 diabetes type 2

<table>
<thead>
<tr>
<th><strong>Trial</strong></th>
<th><strong>Treatments</strong></th>
<th><strong>Patients</strong></th>
<th><strong>Trials design and methods</strong></th>
</tr>
</thead>
</table>

| **Olmesartan vs placebo** | Olmesartan at 40 mg/day versus placebo | Patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction | Parallel groups double-blind Europe (19 countries) |

**ROADMAP**, 2010 [NCT00185159] n=2232/2215 Follow-up: 3.2 y

- Anti hypertensive agents for diabetes type 2 in patients with or without hypertension at http://www.trialresultscenter.org/go-Q414
- Angiotensin-receptor blockers for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q427
- Angiotensin renin system blockade for diabetes type 2 in all type of patients at http://www.trialresultscenter.org/go-Q438

**References**

**ANTIPAF**:
ongoing trial NCT00098137
References

ROADMAP, 2010:

ORIENT, :

5 diabetic kidney disease

<table>
<thead>
<tr>
<th>Trial</th>
<th>Treatments</th>
<th>Patients</th>
<th>Trials design and methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORIENT</td>
<td>olmesartan</td>
<td>patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus</td>
<td>Parallel groups</td>
</tr>
<tr>
<td>[NCT00141453]</td>
<td>versus placebo</td>
<td></td>
<td>double-blind</td>
</tr>
<tr>
<td>n=282/284</td>
<td></td>
<td></td>
<td>Japan, Hong Kong</td>
</tr>
</tbody>
</table>

More details and results:
- All mechanism for diabetic kidney disease in all type of patients at [http://www.trialresultscenter.org/go-Q667](http://www.trialresultscenter.org/go-Q667)

References

ORIENT, :
Entry terms: olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec,